A Study Investigating the Immunologic Effects and Safety of 60-day Treatment of the ALK HDM Tablets in Adult Subjects With HDM-Induced Allergic Rhinitis and/or Atopic Asthma

PHASE3CompletedINTERVENTIONAL
Enrollment

112

Participants

Timeline

Start Date

October 31, 2015

Primary Completion Date

June 30, 2016

Study Completion Date

June 30, 2016

Conditions
AllergyAsthmaRhinitis
Interventions
DRUG

Mitizax

Allergen extract

DRUG

Placebo

Placebo tablet

Trial Locations (9)

115478

National Research Center - Institute of Immunology Federal Medical-Biological Agency of Russia, Moscow

123182

"Russian Medical Academy of Postgraduate Education Studies", Moscow

142190

Hospital of Russian Academy of Science, Troitsk

193231

City out-patient's clinic # 94, Saint Petersburg

220041

Minsk Regional Clinical Hospital, Minsk

220096

City Clinical Hopsital #10, Minsk

420103

Kazan State Medical Academy, Kazan'

Unknown

Smolensk State Medical Academy, Smolensk

Bashkirskiy State Medical University, Ufa

Sponsors

Lead Sponsor

All Listed Sponsors
collaborator

Linical Co., Ltd.

INDUSTRY

collaborator

Datamap

INDUSTRY

lead

Abbott

INDUSTRY